ENT Department, County Emergency Clinical Hospital, 400006 Cluj-Napoca, Romania.
Department of Pharmacology, Toxicology and Clinical Pharmacology, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Medicina (Kaunas). 2023 Jul 13;59(7):1292. doi: 10.3390/medicina59071292.
: Platelet-rich fibrin (PRF) membrane plays an important role in cell proliferation and aids in healing. This study aimed to assess the safety and efficacy of the addition of PRF to the graft in tympanoplasty. : A retrospective study was conducted involving 47 patients with chronic dry eardrum perforation, who were candidates for different types of tympanoplasty (type I-IV). The study took place in the ENT department, County Emergency Clinical Hospital of Cluj-Napoca. In group 1 (27 patients) tympanoplasty was performed with a cartilage graft, while in group 2 (20 patients) a cartilage graft was used with the addition of a PRF membrane. The PRF clot was extracted and transformed into a thin membrane. Postoperative evaluation included otoendoscopy and otomicroscopy at 1, 3, 6, and 12 months after surgery, as well as pure-tone audiometry at 12 months. : Postoperative follow-up at 1, 3, 6, and 12 months showed a higher rate of graft survival in the PRF group than in the non-PRF group. At the 12-month mark, a successful outcome was observed in 95.0% of patients in the PRF group, while the success rate in group 1 was 70.4% ( < 0.05). The postoperative hearing threshold value was statistically significantly lower in the group with PRF, compared to the non-PRF group, being 18.4 ± 10.4 dB and 27.6 ± 16.2 dB ( < 0.001), respectively. Although the postoperative air-bone gap value did not differ significantly between groups, there was a greater improvement in the PRF group ( < 0.7). The PRF was well tolerated, and the incisions healed perfectly. : The PRF membrane increases the rate of autograft survival and is therefore an effective material for patients with chronic perforations of the tympanic membrane.
富血小板纤维蛋白(PRF)膜在细胞增殖中起着重要作用,并有助于愈合。本研究旨在评估在鼓室成形术中添加 PRF 移植物的安全性和有效性。
这是一项回顾性研究,涉及 47 名患有慢性干性鼓膜穿孔的患者,他们是不同类型鼓室成形术(I-IV 型)的候选者。该研究在克卢日-纳波卡县急诊临床医院的耳鼻喉科进行。在第 1 组(27 名患者)中,使用软骨移植物进行鼓室成形术,而在第 2 组(20 名患者)中,使用软骨移植物并添加 PRF 膜。PRF 凝块被提取并转化为薄膜。术后评估包括术后 1、3、6 和 12 个月的耳内镜和耳显微镜检查,以及术后 12 个月的纯音测听。
术后 1、3、6 和 12 个月的随访显示,PRF 组的移植物存活率高于非 PRF 组。在第 12 个月,PRF 组 95.0%的患者获得成功,而非 PRF 组的成功率为 70.4%(<0.05)。PRF 组术后听力阈值明显低于非 PRF 组,分别为 18.4±10.4dB 和 27.6±16.2dB(<0.001)。虽然两组间术后气骨导差无显著差异,但 PRF 组的改善更为显著(<0.7)。PRF 耐受良好,切口愈合完美。
PRF 膜提高了自体移植物的存活率,因此是慢性鼓膜穿孔患者的有效材料。